Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L.

Arthritis Rheum. 2013 Nov;65(11):2954-62. doi: 10.1002/art.38093.

2.

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.

Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L.

J Am Acad Dermatol. 2015 Mar;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009. Epub 2015 Jan 14.

3.

Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.

Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K.

Arthritis Rheum. 2012 Feb;64(2):513-22. doi: 10.1002/art.33403.

4.

Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.

Ishikawa A, Muro Y, Sugiura K, Akiyama M.

Rheumatology (Oxford). 2012 Jul;51(7):1181-7. doi: 10.1093/rheumatology/kes033. Epub 2012 Mar 16.

PMID:
22427409
5.

Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.

Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, Song YW.

Mod Rheumatol. 2014 Nov;24(6):945-8. doi: 10.3109/14397595.2014.896494. Epub 2014 Mar 26.

PMID:
24670134
6.

Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, Tincani A, Ross SJ, Chan JY, Pauley BA, Chan EK, Satoh M.

Arthritis Res Ther. 2012 Apr 30;14(2):R97. doi: 10.1186/ar3822.

7.

Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776. doi: 10.1002/acr.23188.

PMID:
28085235
8.

Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.

Matsuura E, Ishiguro N, Katsumata Y, Urano W, Yamanaka H, Kondo M, Kuwana M, Kaji K, Hamaguchi Y, Fujimoto M, Kawashima M.

Eur J Dermatol. 2012 Sep-Oct;22(5):668-71. doi: 10.1684/ejd.2012.1824.

PMID:
22992252
9.

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.

Kubeček O, Soukup T, Paulík A, Kopecký J.

BMC Cancer. 2016 Aug 25;16(1):684. doi: 10.1186/s12885-016-2715-1.

10.

Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.

Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1909-1914. doi: 10.1002/acr.23210. Epub 2017 Nov 2.

PMID:
28129490
11.

Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.

Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I, Franceschini F, Cantarini L, Satoh M, Selmi C.

Clin Rheumatol. 2017 Feb;36(2):469-475. doi: 10.1007/s10067-016-3453-0. Epub 2016 Oct 20.

PMID:
27761751
12.

Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D.

JAMA Dermatol. 2014 Jul;150(7):724-9. doi: 10.1001/jamadermatol.2013.10416.

13.

Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.

Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Oohata S, Okita H, Yahata T, Someya F, Inoue K, Murono S, Fujimoto M, Takehara K.

PLoS One. 2016 May 11;11(5):e0154746. doi: 10.1371/journal.pone.0154746. eCollection 2016.

14.

Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.

Muro Y, Ishikawa A, Sugiura K, Akiyama M.

Rheumatology (Oxford). 2012 Aug;51(8):1508-13. doi: 10.1093/rheumatology/kes073. Epub 2012 Apr 25.

PMID:
22539482
15.

Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, Chan JY, Chan EK, Satoh M, Franceschini F.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):891-7. Epub 2014 Aug 15.

PMID:
25151986
16.

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, Cooper RG, Oddis CV, Ramanan AV, Davidson JE, McHugh NJ; Juvenile Dermatomyositis Research Group, UK and Ireland.

Arthritis Rheum. 2009 Jun;60(6):1807-14. doi: 10.1002/art.24547.

17.

Polymyositis and dermatomyositis as a risk of developing cancer.

Jakubaszek M, Kwiatkowska B, Maślińska M.

Reumatologia. 2015;53(2):101-5. doi: 10.5114/reum.2015.51510. Epub 2015 May 18. Review.

18.

Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options.

Fredi M, Bartoli F, Cavazzana I, Ceribelli A, Carabellese N, Tincani A, Satoh M, Franceschini F.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):303-308. Epub 2016 Nov 14.

19.

Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.

Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group.

Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753. Epub 2016 Oct 9.

20.

Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.

Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T.

Rheumatology (Oxford). 2010 Sep;49(9):1726-33. doi: 10.1093/rheumatology/keq153. Epub 2010 May 25.

PMID:
20501546

Supplemental Content

Support Center